Predictive models to guide immunotherapy combinations for melanoma
Official title: PROJECT 2: Development and Refinement of Predictive Models for Designing Immunotherapy Combination Treatments
Funded at Institute for Systems Biology · NIH-11415805 · Data updated 2026-11-12
A study to build and refine computer models that help design better combination immunotherapies for melanoma patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Institute for Systems Biology NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 22, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $416,280 |
| NIH project number | 5U54CA274509-05 |
| Project ID | NIH-11415805 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with cutaneous melanoma who may be eligible for immune and targeted therapy combinations and who participate in related clinical trials.
✕Less likely to help
Patients not planned for or unable to participate in related trials or immune-targeted regimens may not directly benefit.
What this research studies
This project aims to create predictive models that integrate deep phenotyping, spatial and temporal data to guide how immune therapies and targeted drugs can be sequenced for melanoma. It uses active learning and iterative approaches to test model predictions in a preclinical and clinical design context, with the goal of improving trial design and patient outcomes. By accounting for both tumor-intrinsic factors and the immune environment, the work seeks to identify regimens that prevent or overcome resistance to MAPK pathway inhibitors and immune therapies. Patients could benefit from more effective, personalized treatment sequences in future trials.
Why it matters
Potential benefit: If successful, patients could receive better-structured combination therapies with higher chances of durable responses.
How similar studies have gone: Prior work has shown that integrating immune factors with targeted therapies can influence outcomes, but the exact predictive models and sequencing strategies are still being developed.
Where this research is happening
-
Institute for Systems Biology
Seattle, United States Active
Researchers
- Principal investigator: Thorsson, Vesteinn — Institute for Systems Biology
- Study coordinator: Thorsson, Vesteinn
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.